Gili Hart

CEO
SpliSense Ltd., Jerusalem, Israel

Poster(s):

• (604) SpliSense’s ASO SPL84-23-1 Properly Distributes and is Retained in CF-like Mice Lungs
  Thursday, November 3, 2022

  12:00 PM – 12:40 PM ET

• (625) Manufacturing and Device Development for SPL84-23-1, an Inhaled Antisense Oligonucleotide, Supporting a First-in-Human Clinical Study in CF Patients Carrying the 3849+10kb C-to-T mutation
  Thursday, November 3, 2022

  12:45 PM – 1:25 PM ET